California Plans To Create Own Generics Label
Aiming To Regain Power From ‘Greedy’ Industry
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
You may also be interested in...
Responding to a California district court’s denial of an injunction to prevent the enactment of the US state’s legislation banning ‘pay-for-delay’ settlement deals, the AAM has confirmed plans to immediately appeal the decision.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
Plans unveiled by the UK’s main opposition party to set up a publicly-owned generics manufacturer fail to recognize the benefits and savings created through multisource competition, the country’s generics industry believes.